

Session A. Breast cancer

A65 **Primary prophylaxis of neutropenia in women affected by breast cancer undergoing adjuvant chemotherapy with fec 100 +/- docetaxel: comparison of efficacy and tolerability between lenograstim and pegfilgrastim**

L. Rossi¹, A. Papa², F. Tomao³, D. Caruso², F. Ricci¹, M. Verrico², E. Giordani², F. Perrone Congedi², D. Giannarelli⁴, E. Zaccarelli², M. Minozzi¹, G.P. Spinelli¹, V. Stati², S. Tomao²

¹Ospedale Santa Maria Goretti, Latina

²Università "La Sapienza" Roma - Polo Pontino, Latina

³Università "La Sapienza", Roma, Dipartimento di Ginecologia e Ostetricia, Roma

⁴Regina Elena National Cancer Institute, Roma

Introduction: myelosuppression is primary toxicity of many chemotherapy regimens and limits their applicability. Use of G-CSF is important to reduce incidence of febrile neutropenia, but is burdened with bone pain.

Objectives: evaluate safety and toxicity of a single injection of pegfilgrastim compared to daily administration of lenograstim in breast cancer patient undergoing adjuvant chemotherapy.

Methods: single injection of Pegfilgrastim compared to 5 daily administrations of Lenograstim in a population of 56 women undergoing chemotherapy with FEC-100 for 6 cycles (Group A) or 3 FEC-100 followed by 3 DOCETAXEL-100 (Group B).

Results: In Group A, 40% of patients showed Neutropenia-G4, 35,3% of those treated with Lenograstim, while 44,4% of those treated with Pegfilgrastim. In Group B, 57,1% of patients showed Neutropenia-G4: 75,0% of those treated with Lenograstim and 33,3% of patients treated with Pegfilgrastim ($p = 0,005$). Overall, 30,4% of all patients developed BP with intensity of 7-10 second Numeric Rating Scale. Bone Pain incidence was significantly higher in Group B than in Group A (52,4% vs 17,1%, $p = 0,005$), with no significant differences between Lenograstim and Pegfilgrastim. In both groups, the average duration of Bone Pain was 4-6 days.

Conclusions: Both G-CSFs showed efficacy in reduction of Neutropenia, but Pegfilgrastim showed a better action with similar side effects in Group B. Moreover, Pegfilgrastim could be a better choice for patient's compliance because of single injection in front of 5 necessary for L. Overall, Bone Pain incidence was significantly higher in Group B than in Group A ($p = 0,005$), with no significant differences between Lenograstim and Pegfilgrastim.